July 12, 2019
Ono Pharmaceutical has grabbed rights to Stanford University spinout Forty Seven’s macrophage immune checkpoint inhibitor 5F9, an anti-CD47 antibody, for its exclusive development and commercialization in certain Asian markets including Japan. Under the deal announced on July 11, Ono acquired...read more